OpGen, Inc. (NASDAQ:OPGN) Sees Large Decrease in Short Interest

OpGen, Inc. (NASDAQ:OPGN) was the recipient of a significant drop in short interest in the month of April. As of April 15th, there was short interest totalling 164,100 shares, a drop of 92.6% from the March 31st total of 2,230,000 shares. Based on an average daily volume of 1,650,000 shares, the days-to-cover ratio is presently 0.1 days. Currently, 1.4% of the shares of the company are sold short.

Analysts Set New Price Targets

Separately, StockNews.com started coverage on OpGen in a report on Monday. They set a “sell” rating for the company.

OpGen Price Performance

Shares of NASDAQ:OPGN traded down $0.03 during midday trading on Thursday, reaching $0.53. The company’s stock had a trading volume of 195,649 shares, compared to its average volume of 1,387,221. OpGen has a fifty-two week low of $0.17 and a fifty-two week high of $3.84. The company has a market capitalization of $6.71 million, a P/E ratio of -0.08 and a beta of -0.71. The business’s fifty day simple moving average is $0.57 and its 200-day simple moving average is $0.51.

About OpGen

OpGen, Inc, a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits.